Further characterization of FXYD5/Dysadherin expression in Endometrial Cancer and its association to tumor progression and treatment

CATALANO, D; BESSO MJ; VAZQUEZ LEVIN MH

Mar del Plata

Congreso; eunión de Sociedades de Biociencias 2020 LXV Reunión Anual De La Sociedad Argentina De Investigación Clínica (Saic) LXVIII Reunión Anual De La Sociedad Argentina De Inmunología (SAI) Reunión Anual De La Sociedad Argentina De Fisiología (SAFIS); 2020

Sociedad Argetntina de Investigacion Clinica

Aim: Endometrial cancer (EC) is 6th most frequent women cancer worldwide. Stage IA endometroid EC (EEC) patients have good prognosis, and a conservative treatment of Medroxyprogesterone acetate (MPA) is applied to patients attempting fertility preservation or unsuitable candidates for surgery. However, MPA response is partial or nule, and recurrence is reported. Using cell models and patient samples, we demonstrated an increased expression of FXYD5/Dysadherin (Dys) in ECC. In cell models, we found a negative association between Dys and E-cadherin/CDH1, activation of TGF-β and NF-κB pathways, and cytokine expression. In this study, we further evaluated Dys expression, association with ECC progression and with MPA response. M&M: mRNA expression of Dys and related molecules was analyzed in EC patient datasets, and in MPA-resistant Ishikawa EEC cells and control (GSE121367). Results: A negative (p